ALOT compared with ESPR: revenue, margins and what each company keeps, and the suppliers and customers both name

ALOTAstroNova, Inc.

Mkt capRevenueRevenue

ESPREsperion Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ALOTAstroNova, Inc.

ESPREsperion Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALOT

No earnings history for ALOT.

ESPR

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q1 FY26±15.3%▼−11.18%×0.73

Q4 FY25±9.3%▼−8.51%×0.91

Q3 FY25±21.8%▼−14.97%×0.69

Aug 5 '25±19.8%▲+8.72%×0.44

= impliedALOT realized, solidESPR realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

ALOTAstroNova, Inc.

28.99▼−0.01%· post 29.00· delayed

Mkt cap$224.6MRevenue$39MQ1 FY27Revenue$151MFY26

ESPREsperion Therapeutics, Inc.

3.19▼−0.16%· post 3.20· delayed

After hoursAug 26 '26delayed

Mkt cap$818.6MRevenue$80MQ1 FY26Revenue$403MFY25

Compare

After hoursAug 26 '26delayed

ALOTAstroNova, Inc.

ESPREsperion Therapeutics, Inc.

28.99▼−0.01%post 29.00delayed

Price

3.19▼−0.16%post 3.20delayed

$224.6M

Mkt cap

$818.6M

Q1 FY27$39M

Revenue

$80MQ1 FY26

FY26$151M

Revenue

$403MFY25

ALOT28.99▼−0.01%vsESPR3.19▼−0.16%After hoursAug 26 '26delayed